LC
TGTX icon

Lindbrook Capital’s TG Therapeutics TGTX Stock Holding History

Lindbrook Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$34.1K Buy
864
+37
+4% +$1.25K ﹤0.01% 1140
2024
Q4 		$24.9K Buy
827
+1
+0.1% +$29 ﹤0.01% 1152
2024
Q3 		$19.3K Buy
826
+72
+10% +$1.57K ﹤0.01% 1320
2024
Q2 		$13.4K Buy
754
+42
+6% +$670 ﹤0.01% 1474
2024
Q1 		$10.8K Sell
712
-70
-9% -$1.11K ﹤0.01% 1527
2023
Q4 		$13.4K Buy
782
+393
+101% +$4.57K ﹤0.01% 1388
2023
Q3 		$3.25K Buy
389
+44
+13% +$613 ﹤0.01% 1951
2023
Q2 		$8.57K Buy
345
+15
+5% +$387 ﹤0.01% 1559
2023
Q1 		$4.96K Buy
330
+27
+9% +$410 ﹤0.01% 1851
2022
Q4 		$3.58K Buy
303
+203
+203% +$1.47K ﹤0.01% 1975
2022
Q3 		$1K Sell
100
-240
-71% -$1.57K ﹤0.01% 2501
2022
Q2 		$1K Sell
340
-57
-14% -$356 ﹤0.01% 2377
2022
Q1 		$4K Sell
397
-721
-64% -$8.34K ﹤0.01% 1749
2021
Q4 		$21K Sell
1,118
-1,382
-55% -$35.9K ﹤0.01% 1003
2021
Q3 		$83K Sell
2,500
-500
-17% -$15.5K 0.02% 307
2021
Q2 		$116K Buy
3,000
+400
+15% +$15.7K 0.03% 264
2021
Q1 		$125K Buy
2,600
+1,100
+73% +$52.9K 0.03% 235
2020
Q4 		$78K Buy
1,500
+500
+50% +$16.9K 0.02% 289
2020
Q3 		$27K Hold
1,000
– – 0.01% 529
2020
Q2 		$19K Buy
+1,000
New +$16.1K 0.01% 627
2019
Q2 		– Sell
-1,000
Closed -$8K – 1507
2019
Q1 		$8K Hold
1,000
– – ﹤0.01% 968
2018
Q4 		$4K Buy
+1,000
New +$4.97K ﹤0.01% 1080

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lindbrook Capital's TGTX Position: Q1 2025 in Review

Lindbrook Capital increased its TG Therapeutics (TGTX) stake by 4.5% in Q1 2025, buying an estimated $1.25K and bringing the position to 864 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

Lindbrook Capital first reported a position in TGTX in Q4 2018 and has held it in 22 quarters since. The position peaked at $125K in Q1 2021. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

  • Lindbrook Capital held 864 shares of TG Therapeutics worth $34.1K as of Q1 2025.
  • Lindbrook Capital bought 37 TG Therapeutics shares in Q1 2025, an estimated $1.25K.
  • TG Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1140 holding.
  • Lindbrook Capital first reported a position in TG Therapeutics in Q4 2018 and has held it in 22 quarters since.
  • Lindbrook Capital's TG Therapeutics position peaked at $125K in Q1 2021.
  • 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.